HISTOCELL SL

Their core work

Histocell is a Spanish biotech SME based in the Basque Country specializing in cell therapy products and biomaterial-based medical devices for tissue regeneration. They develop therapies using mesenchymal stem cells (particularly from adipose tissue) and bio-scaffolds for applications ranging from stroke recovery to bone fracture repair and oral mucosa regeneration. Their work bridges cell engineering, growth factor delivery, and implant coating technologies to create clinically relevant regenerative medicine products.

What they specialise in

How they've shifted over time

Histocell's early H2020 work (2015-2017) centered on cell therapy and stem cell science — using mesenchymal stem cells for stroke recovery (RESSTORE) and adipose tissue regeneration (SCAFFY), with a strong clinical and biological emphasis. Their more recent activity (2017-2020 onward) has shifted toward engineered biomaterials, implant coatings, and medical devices for hard tissue repair (HEALIKICK), signaling a move from pure cell biology toward combination products that integrate growth factors with physical scaffolds. This evolution suggests a maturing pipeline moving from research-stage cell therapies toward more product-oriented medical device development.

Histocell is moving from cell-based therapies toward combination medical devices integrating biomaterials with growth factors, positioning them closer to commercial product development.

How they like to work

Histocell primarily participates as a partner rather than leading consortia, having coordinated only 1 of 4 projects (the small SME Instrument Phase 1 feasibility study NEOFIBRIN). They operate within moderately large European consortia, having worked with 37 unique partners across 10 countries, indicating broad network reach for an SME of their size. Their participation pattern suggests they bring specialized cell engineering and biomaterial expertise to larger research teams rather than driving consortium strategy.

With 37 unique consortium partners spanning 10 countries, Histocell has built a solid European network for a small biotech company. Their partnerships likely cluster around regenerative medicine research hubs in Western Europe, consistent with the RESSTORE and HEALIKICK consortia.

What sets them apart

Histocell occupies a valuable niche as an SME that bridges cell biology and medical device engineering — they can work with living cells (stem cells, growth factors) AND with physical materials (scaffolds, implant coatings). This dual capability is uncommon among small companies and makes them a strong partner for translational projects that need to move from lab-stage biology to a regulated product. Their Basque Country base also connects them to Spain's growing biotech ecosystem around Bilbao/Derio.

Highlights from their portfolio

• HEALIKICK
  Their largest project by far (EUR 848K), running until 2026, representing their current strategic direction toward bone repair medical devices with growth factor coatings.
• RESSTORE
  A major European stroke therapy consortium demonstrating Histocell's capability in clinical-grade stem cell production for a high-impact neurological condition.
• NEOFIBRIN
  Their only coordinated project — an SME Instrument Phase 1 for oral mucosa regeneration, showing entrepreneurial initiative to develop their own product line.